Targeting cancer hallmark vulnerabilities in hematologic malignancies by interfering with Hedgehog/GLI signaling

2.

Von Hoff

DD

,

LoRusso

PM

,

Rudin

CM

, et al.

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

.

N Engl J Med

.

2009

;

361

(

12

):

1164

-

1172

.

3.

Dlugosz

A

,

Agrawal

S

,

Kirkpatrick

P

.

Vismodegib

.

Nat Rev Drug Discov

.

2012

;

11

(

6

):

437

-

438

.

4.

Rudin

CM

.

Vismodegib

.

Clin Cancer Res

.

2012

;

18

(

12

):

3218

-

3222

.

5.

Norsworthy

KJ

,

By

K

,

Subramaniam

S

, et al.

FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia

.

Clin Cancer Res

.

2019

;

25

(

20

):

6021

-

6025

.

6.

Rohatgi

R

,

Milenkovic

L

,

Scott

MP

.

Patched1 regulates hedgehog signaling at the primary cilium

.

Science

.

2007

;

317

(

5836

):

372

-

376

.

7.

Goetz

SC

,

Anderson

KV

.

The primary cilium: a signalling centre during vertebrate development

.

Nat Rev Genet

.

2010

;

11

(

5

):

331

-

344

.

8.

Zhang

Y

,

Beachy

PA

.

Cellular and molecular mechanisms of Hedgehog signalling

.

Nat Rev Mol Cell Biol

.

2023

;

24

(

9

):

668

-

687

.

9.

Aberger

F

,

Ruiz i Altaba

A

.

Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy

.

Semin Cell Dev Biol

.

2014

;

33

(

100

):

93

-

104

.

10.

Jiang

J

.

Hedgehog signaling mechanism and role in cancer

.

Semin Cancer Biol

.

2022

;

85

:

107

-

122

.

11.

Ingham

PW

.

Hedgehog signaling

.

Curr Top Dev Biol

.

2022

;

149

:

1

-

58

.

12.

Prosser

SL

,

Morrison

CG

.

Centrin2 regulates CP110 removal in primary cilium formation

.

J Cell Biol

.

2015

;

208

(

6

):

693

-

701

.

13.

Singh

M

,

Chaudhry

P

,

Merchant

AA

.

Primary cilia are present on human blood and bone marrow cells and mediate Hedgehog signaling

.

Exp Hematol

.

2016

;

44

(

12

):

1181

-

1187.e2

.

14.

Campbell

V

,

Tarafdar

A

,

Dobbin

E

, et al.

Unravelling the complexities of Hedgehog mediated signal transduction in acute myeloid leukaemia and normal haematopoiesis

.

Blood

.

2016

;

128

(

22

):

2881

.

15.

Cassioli

C

,

Baldari

CT

.

A ciliary view of the immunological synapse

.

Cells

.

2019

;

8

(

8

):

789

.

16.

de la Roche

M

,

Ritter

AT

,

Angus

KL

, et al.

Hedgehog signaling controls T cell killing at the immunological synapse

.

Science

.

2013

;

342

(

6163

):

1247

-

1250

.

17.

Hanna

J

,

Beke

F

,

O'Brien

LM

, et al.

Cell-autonomous Hedgehog signaling controls Th17 polarization and pathogenicity

.

Nat Commun

.

2022

;

13

(

1

):

4075

.

18.

Toriyama

M

,

Rizaldy

D

,

Nakamura

M

, et al.

Dendritic cell proliferation by primary cilium in atopic dermatitis

.

Front Mol Biosci

.

2023

;

10

:

1149828

.

19.

Riobó

NA

,

Lu

K

,

Ai

X

,

Haines

GM

,

Emerson

CP

.

Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling

.

Proc Natl Acad Sci U S A

.

2006

;

103

(

12

):

4505

-

4510

.

20.

Stecca

B

,

Mas

C

,

Clement

V

, et al.

Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways

.

Proc Natl Acad Sci U S A

.

2007

;

104

(

14

):

5895

-

5900

.

21.

Atwood

SX

,

Li

M

,

Lee

A

,

Tang

JY

,

Oro

AE

.

GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas

.

Nature

.

2013

;

494

(

7438

):

484

-

488

.

22.

Tang

Y

,

Gholamin

S

,

Schubert

S

, et al.

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition

.

Nat Med

.

2014

;

20

(

7

):

732

-

740

.

23.

Canettieri

G

,

Di Marcotullio

L

,

Greco

A

, et al.

Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation

.

Nat Cell Biol

.

2010

;

12

(

2

):

132

-

142

.

24.

Gruber

W

,

Peer

E

,

Elmer

DP

, et al.

Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance

.

Int J Cancer

.

2018

;

142

(

5

):

968

-

975

.

25.

Mirza

AN

,

Fry

MA

,

Urman

NM

, et al.

Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment

.

JCI Insight

.

2017

;

2

(

21

):

e97071

.

26.

Wang

Y

,

Ding

Q

,

Yen

CJ

, et al.

The crosstalk of mTOR/S6K1 and Hedgehog pathways

.

Cancer Cell

.

2012

;

21

(

3

):

374

-

387

.

27.

Ji

Z

,

Mei

FC

,

Xie

J

,

Cheng

X

.

Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells

.

J Biol Chem

.

2007

;

282

(

19

):

14048

-

14055

.

28.

Nolan-Stevaux

O

,

Lau

J

,

Truitt

ML

, et al.

GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation

.

Genes Dev

.

2009

;

23

(

1

):

24

-

36

.

29.

Riobo

NA

,

Haines

GM

,

Emerson

CP

.

Protein kinase C-delta and mitogen-activated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling

.

Cancer Res

.

2006

;

66

(

2

):

839

-

845

.

30.

Schnidar

H

,

Eberl

M

,

Klingler

S

, et al.

Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway

.

Cancer Res

.

2009

;

69

(

4

):

1284

-

1292

.

31.

Whisenant

TC

,

Ho

DT

,

Benz

RW

, et al.

Computational prediction and experimental verification of new MAP kinase docking sites and substrates including Gli transcription factors

.

PLoS Comput Biol

.

2010

;

6

(

8

):

e1000908

.

32.

Peer

E

,

Aichberger

SK

,

Vilotic

F

, et al.

Casein kinase 1D encodes a novel drug target in Hedgehog-GLI-driven cancers and tumor-initiating cells resistant to SMO inhibition

.

Cancers (Basel)

.

2021

;

13

(

16

):

4227

.

33.

Jia

H

,

Liu

Y

,

Xia

R

, et al.

Casein kinase 2 promotes Hedgehog signaling by regulating both smoothened and Cubitus interruptus

.

J Biol Chem

.

2010

;

285

(

48

):

37218

-

37226

.

34.

Purzner

T

,

Purzner

J

,

Buckstaff

T

, et al.

Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma

.

Sci Signal

.

2018

;

11

(

547

):

eaau5147

.

35.

Mao

J

,

Maye

P

,

Kogerman

P

, et al.

Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1

.

J Biol Chem

.

2002

;

277

(

38

):

35156

-

35161

.

36.

Gruber

W

,

Hutzinger

M

,

Elmer

DP

, et al.

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance

.

Oncotarget

.

2016

;

7

(

6

):

7134

-

7148

.

37.

Singh

R

,

Dhanyamraju

PK

,

Lauth

M

.

DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway

.

Oncotarget

.

2017

;

8

(

1

):

833

-

845

.

38.

Whitson

RJ

,

Lee

A

,

Urman

NM

, et al.

Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas

.

Nat Med

.

2018

;

24

(

3

):

271

-

281

.

39.

Bhardwaj

G

,

Murdoch

B

,

Wu

D

, et al.

Sonic Hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation

.

Nat Immunol

.

2001

;

2

(

2

):

172

-

180

.

40.

Kobune

M

,

Ito

Y

,

Kawano

Y

, et al.

Indian Hedgehog gene transfer augments hematopoietic support of human stromal cells including NOD/SCID-beta2m-/- repopulating cells

.

Blood

.

2004

;

104

(

4

):

1002

-

1009

.

41.

Trowbridge

JJ

,

Scott

MP

,

Bhatia

M

.

Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration

.

Proc Natl Acad Sci U S A

.

2006

;

103

(

38

):

14134

-

14139

.

42.

Dierks

C

,

Beigi

R

,

Guo

G-R

, et al.

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

.

Cancer Cell

.

2008

;

14

(

3

):

238

-

249

.

43.

Uhmann

A

,

Dittmann

K

,

Nitzki

F

, et al.

The Hedgehog receptor Patched controls lymphoid lineage commitment

.

Blood

.

2007

;

110

(

6

):

1814

-

1823

.

44.

Siggins

SL

,

Nguyen

NY

,

McCormack

MP

, et al.

The Hedgehog receptor Patched1 regulates myeloid and lymphoid progenitors by distinct cell-extrinsic mechanisms

.

Blood

.

2009

;

114

(

5

):

995

-

1004

.

45.

Gao

J

,

Graves

S

,

Koch

U

, et al.

Hedgehog signaling is dispensable for adult hematopoietic stem cell function

.

Cell Stem Cell

.

2009

;

4

(

6

):

548

-

558

.

46.

Hofmann

I

,

Stover

EH

,

Cullen

DE

, et al.

Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis

.

Cell Stem Cell

.

2009

;

4

(

6

):

559

-

567

.

47.

Solanki

A

,

Lau

CI

,

Saldaña

JI

,

Ross

S

,

Crompton

T

.

The transcription factor Gli3 promotes B cell development in fetal liver through repression of Shh

.

J Exp Med

.

2017

;

214

(

7

):

2041

-

2058

.

48.

Barbarulo

A

,

Lau

CI

,

Mengrelis

K

, et al.

Hedgehog signalling in the embryonic mouse thymus

.

J Dev Biol

.

2016

;

4

(

3

):

22

.

49.

Yánez

DC

,

Lau

CI

,

Chawda

MM

,

Ross

S

,

Furmanski

AL

,

Crompton

T

.

Hedgehog signaling promotes TH2 differentiation in naive human CD4 T cells

.

J Allergy Clin Immunol

.

2019

;

144

(

5

):

1419

-

1423.e1

.

50.

Furmanski

AL

,

Barbarulo

A

,

Solanki

A

, et al.

The transcriptional activator Gli2 modulates T-cell receptor signalling through attenuation of AP-1 and NFκB activity

.

J Cell Sci

.

2015

;

128

(

11

):

2085

-

2095

.

51.

Mengrelis

K

,

Lau

CI

,

Rowell

J

, et al.

Sonic Hedgehog is a determinant of γδ T-cell differentiation in the thymus

.

Front Immunol

.

2019

;

10

:

1629

.

52.

Syn

WK

,

Witek

RP

,

Curbishley

SM

, et al.

Role for hedgehog pathway in regulating growth and function of invariant NKT cells

.

Eur J Immunol

.

2009

;

39

(

7

):

1879

-

1892

.

53.

Lau

CI

,

Outram

SV

,

Saldaña

JI

,

Furmanski

AL

,

Dessens

JT

,

Crompton

T

.

Regulation of murine normal and stress-induced erythropoiesis by Desert Hedgehog

.

Blood

.

2012

;

119

(

20

):

4741

-

4751

.

54.

Hanahan

D

,

Weinberg

RA

.

The hallmarks of cancer

.

Cell

.

2000

;

100

(

1

):

57

-

70

.

55.

Hanahan

D

,

Weinberg

RA

.

Hallmarks of cancer: the next generation

.

Cell

.

2011

;

144

(

5

):

646

-

674

.

56.

Hanahan

D

.

Hallmarks of cancer: new dimensions

.

Cancer Discov

.

2022

;

12

(

1

):

31

-

46

.

57.

Goodrich

LV

,

Milenković

L

,

Higgins

KM

,

Scott

MPS

.

Altered neural cell fates and medulloblastoma in mouse Patched mutants

.

Science

.

1997

;

277

(

5329

):

1109

-

1113

.

58.

Regl

G

,

Kasper

M

,

Schnidar

H

, et al.

The zinc-finger transcription factor GLI2 antagonizes contact inhibition and differentiation of human epidermal cells

.

Oncogene

.

2004

;

23

(

6

):

1263

-

1274

.

59.

Dahmane

N

,

Ruiz i Altaba

A

.

Sonic Hedgehog regulates the growth and patterning of the cerebellum

.

Development

.

1999

;

126

(

14

):

3089

-

3100

.

60.

Matsui

W

,

Huff

CA

,

Wang

Q

, et al.

Characterization of clonogenic multiple myeloma cells

.

Blood

.

2004

;

103

(

6

):

2332

-

2336

.

61.

Peacock

CD

,

Wang

Q

,

Gesell

GS

, et al.

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma

.

Proc Natl Acad Sci U S A

.

2007

;

104

(

10

):

4048

-

4053

.

62.

Jacak

J

,

Schnidar

H

,

Muresan

L

, et al.

Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout

.

J Biotechnol

.

2013

;

164

(

4

):

525

-

530

.

63.

Martello

M

,

Solli

V

,

Termini

R

, et al.

Identification of a maturation plasma cell index through a highly sensitive droplet digital PCR assay gene expression signature validation in newly diagnosed multiple myeloma patients

.

Int J Mol Sci

.

2022

;

23

(

20

):

12450

.

64.

Martello

M

,

Remondini

D

,

Borsi

E

, et al.

Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis

.

Leukemia

.

2016

;

30

(

9

):

1869

-

1876

.

65.

Dierks

C

,

Grbic

J

,

Zirlik

K

, et al.

Essential role of stromally induced hedgehog signaling in B-cell malignancies

.

Nat Med

.

2007

;

13

(

8

):

944

-

951

.

66.

Blotta

S

,

Jakubikova

J

,

Calimeri

T

, et al.

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

.

Blood

.

2012

;

120

(

25

):

5002

-

5013

.

67.

Lazzari

E

,

Mondala

PK

,

Santos

ND

, et al.

Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma

.

Nat Commun

.

2017

;

8

(

1

):

1922

.

68.

Zhang

Z

,

Zhang

R

,

Hao

C

,

Pei

X

,

Li

J

,

Wang

L

.

GANT61 and valproic acid synergistically inhibited multiple myeloma cell proliferation via Hedgehog signaling pathway

.

Med Sci Monit

.

2020

;

26

:

e920541

.

69.

Zhang

Z

,

Hao

C

,

Zhang

R

,

Pei

X

,

Li

J

,

Wang

L

.

A Gli inhibitor GANT61 suppresses cell proliferation, promotes cell apoptosis and induces G1/G0 cycle retardation with a dose- and time-dependent manner through inhibiting Notch pathway in multiple myeloma

.

Cell Cycle

.

2020

;

19

(

16

):

2063

-

2073

.

70.

Luo

H

,

Zhang

D

,

Wang

F

, et al.

ALCAM-EGFR interaction regulates myelomagenesis

.

Blood Adv

.

2021

;

5

(

23

):

5269

-

5282

.

71.

Zhang

Y

,

Yao

G

,

Yang

X

,

Qiu

T

,

Wang

S

.

Mechanism of targeting the Hedgehog signaling pathway against chemotherapeutic resistance in multiple myeloma

.

J Oncol

.

2022

;

2022

:

1399697

.

72.

Liu

Z

,

Xu

J

,

He

J

, et al.

A critical role of autocrine Sonic Hedgehog signaling in human CD138+ myeloma cell survival and drug resistance

.

Blood

.

2014

;

124

(

13

):

2061

-

2071

.

73.

Werner

CA

,

Döhner

H

,

Joos

S

, et al.

High-level DNA amplifications are common genetic aberrations in B-cell neoplasms

.

Am J Pathol

.

1997

;

151

(

2

):

335

-

342

.

74.

González-Gugel

E

,

Villa-Morales

M

,

Santos

J

, et al.

Down-regulation of specific miRNAs enhances the expression of the gene Smoothened and contributes to T-cell lymphoblastic lymphoma development

.

Carcinogenesis

.

2013

;

34

(

4

):

902

-

908

.

75.

Singh

RR

,

Cho-Vega

JH

,

Davuluri

Y

, et al.

Sonic Hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma

.

Cancer Res

.

2009

;

69

(

6

):

2550

-

2558

.

76.

Rao

PH

,

Houldsworth

J

,

Dyomina

K

, et al.

Chromosomal and gene amplification in diffuse large B-cell lymphoma

.

Blood

.

1998

;

92

(

1

):

234

-

240

.

77.

Vega

F

,

Cho-Vega

JH

,

Lennon

PA

, et al.

Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (POT1) and Sonic Hedgehog (SHH) genes

.

Br J Haematol

.

2008

;

142

(

2

):

216

-

226

.

78.

Hegde

GV

,

Munger

CM

,

Emanuel

K

, et al.

Targeting of Sonic Hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma

.

Mol Cancer Ther

.

2008

;

7

(

6

):

1450

-

1460

.

79.

Kim

JE

,

Singh

RR

,

Cho-Vega

JH

, et al.

Sonic Hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma

.

Mod Pathol

.

2009

;

22

(

10

):

1312

-

1320

.

80.

Greaves

WO

,

Kim

JE

,

Singh

RR

, et al.

Glioma-associated oncogene homologue 3, a hedgehog transcription factor, is highly expressed in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma

.

Hum Pathol

.

2011

;

42

(

11

):

1643

-

1652

.

81.

Hegde

GV

,

Nordgren

TM

,

Munger

CM

, et al.

Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of Hedgehog signaling

.

Int J Cancer

.

2012

;

131

(

12

):

2951

-

2960

.

82.

Ramirez

E

,

Singh

RR

,

Kunkalla

K

, et al.

Defining causative factors contributing in the activation of Hedgehog signaling in diffuse large B-cell lymphoma

.

Leuk Res

.

2012

;

36

(

10

):

1267

-

1273

.

83.

Kim

SH

,

Choe

JY

,

Jeon

Y

, et al.

Frequent expression of follicular dendritic cell markers in Hodgkin lymphoma and anaplastic large cell lymphoma

.

J Clin Pathol

.

2013

;

66

(

7

):

589

-

596

.

84.

Yoon

JW

,

Gallant

M

,

Lamm

ML

, et al.

Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma

.

Mol Cancer Res

.

2013

;

11

(

6

):

604

-

615

.

85.

Ghia

EM

,

Rassenti

LZ

,

Neuberg

DS

, et al.

Activation of Hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia

.

Blood

.

2019

;

133

(

25

):

2651

-

2663

.

86.

Liu

S

,

Li

C

,

Xin

P

, et al.

Sonidegib, a Smoothened inhibitor, promotes apoptosis and suppresses proliferation of natural killer/T-cell lymphoma

.

Med Sci Monit

.

2019

;

25

:

8579

-

8586

.

87.

Liu

P

,

Chen

L

.

Inhibition of sonic hedgehog signaling blocks cell migration and growth but induces apoptosis via suppression of FOXQ1 in natural killer/T-cell lymphoma

.

Leuk Res

.

2018

;

64

:

1

-

9

.

88.

Singh

RR

,

Kim

JE

,

Davuluri

Y

, et al.

Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation

.

Leukemia

.

2010

;

24

(

5

):

1025

-

1036

.

89.

Dagklis

A

,

Pauwels

D

,

Lahortiga

I

, et al.

Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia

.

Haematologica

.

2015

;

100

(

3

):

e102

-

105

.

90.

Chang

VY

,

Basso

G

,

Sakamoto

KM

,

Nelson

SF

.

Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia

.

BMC Cancer

.

2013

;

13

:

55

.

91.

Dagklis

A

,

Demeyer

S

,

De Bie

J

, et al.

Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors

.

Blood

.

2016

;

128

(

23

):

2642

-

2654

.

92.

Burns

MA

,

Liao

ZW

,

Yamagata

N

, et al.

Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia

.

Leukemia

.

2018

;

32

(

10

):

2126

-

2137

.

93.

Tosello

V

,

Bongiovanni

D

,

Di Martino

L

, et al.

Responsiveness to Hedgehog pathway inhibitors in T-cell acute lymphoblastic leukemia cells is highly dependent on 5'AMP-activated kinase inactivation

.

Int J Mol Sci

.

2021

;

22

(

12

):

6384

.

94.

Tosello

V

,

Bongiovanni

D

,

Liu

J

, et al.

Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination

.

Leukemia

.

2021

;

35

(

4

):

984

-

1000

.

95.

Qin

Y

,

Jiang

M

,

Tuerxung

N

, et al.

Sonic hedgehog signaling pathway in myelodysplastic syndrome: abnormal activation and jervine intervention

.

Gene

.

2020

;

754

:

144881

.

96.

Lau

BW

,

Huh

K

,

Madero-Marroquin

R

, et al.

Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity

.

Oncogene

.

2019

;

38

(

5

):

687

-

698

.

97.

Zou

J

,

Zhou

Z

,

Wan

L

, et al.

Targeting the Sonic Hedgehog-Gli1 pathway as a potential new therapeutic strategy for myelodysplastic syndromes

.

PLoS One

.

2015

;

10

(

8

):

e0136843

.

98.

Xavier-Ferrucio

JM

,

Pericole

FV

,

Lopes

MR

, et al.

Abnormal Hedgehog pathway in myelodysplastic syndrome and its impact on patients' outcome

.

Haematologica

.

2015

;

100

(

12

):

e491

-

493

.

99.

Zou

J

,

Hong

Y

,

Tong

Y

, et al.

Sonic Hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome

.

Stem Cells Int

.

2015

;

2015

:

957502

.

100.

Bai

LY

,

Chiu

CF

,

Lin

CW

, et al.

Differential expression of Sonic Hedgehog and Gli1 in hematological malignancies

.

Leukemia

.

2008

;

22

(

1

):

226

-

228

.

101.

Kobune

M

,

Takimoto

R

,

Murase

K

, et al.

Drug resistance is dramatically restored by Hedgehog inhibitors in CD34+ leukemic cells

.

Cancer Sci

.

2009

;

100

(

5

):

948

-

955

.

102.

Kobune

M

,

Iyama

S

,

Kikuchi

S

, et al.

Stromal cells expressing Hedgehog-interacting protein regulate the proliferation of myeloid neoplasms

.

Blood Cancer J

.

2012

;

2

(

9

):

e87

.

103.

Wellbrock

J

,

Latuske

E

,

Köhler

J

, et al.

Expression of Hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects

.

Clin Cancer Res

.

2015

;

21

(

10

):

2388

-

2398

.

104.

Chaudhry

P

,

Singh

M

,

Triche

TJ

,

Guzman

M

,

Merchant

AA

.

GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML

.

Blood

.

2017

;

129

(

26

):

3465

-

3475

.

105.

Pabst

C

,

Bergeron

A

,

Lavallée

VP

, et al.

GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo

.

Blood

.

2016

;

127

(

16

):

2018

-

2027

.

106.

He

L

,

Arnold

C

,

Thoma

J

, et al.

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia

.

EMBO Mol Med

.

2022

;

14

(

4

):

e14990

.

107.

Zhou

C

,

Du

J

,

Zhao

L

, et al.

GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia

.

Cell Death Dis

.

2021

;

12

(

3

):

231

.

108.

Tesanovic

S

,

Krenn

PW

,

Aberger

F

.

Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside

.

Front Cell Dev Biol

.

2022

;

10

:

944760

.

109.

Wellbrock

J

,

Behrmann

L

,

Muschhammer

J

, et al.

The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia

.

Ann Hematol

.

2021

;

100

(

12

):

2933

-

2941

.

110.

Latuske

EM

,

Stamm

H

,

Klokow

M

, et al.

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia

.

Oncotarget

.

2017

;

8

(

17

):

29187

-

29201

.

111.

Lim

Y

,

Gondek

L

,

Li

L

, et al.

Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia

.

Sci Transl Med

.

2015

;

7

(

291

):

291ra96

.

112.

Long

B

,

Wang

LX

,

Zheng

FM

, et al.

Targeting GLI1 suppresses cell growth and enhances chemosensitivity in CD34+ enriched acute myeloid leukemia progenitor cells

.

Cell Physiol Biochem

.

2016

;

38

(

4

):

1288

-

1302

.

113.

Zhao

C

,

Chen

A

,

Jamieson

CH

, et al.

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

.

Nature

.

2009

;

458

(

7239

):

776

-

779

.

114.

Su

W

,

Meng

F

,

Huang

L

,

Zheng

M

,

Liu

W

,

Sun

H

.

Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling

.

Exp Hematol

.

2012

;

40

(

5

):

418

-

427

.

115.

Okabe

S

,

Tauchi

T

,

Tanaka

Y

,

Katagiri

S

,

Ohyashiki

K

.

Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells

.

Stem Cells Dev

.

2012

;

21

(

16

):

2939

-

2948

.

116.

Anusha

Dalal H

,

Dalal

H

,

Subramanian

S

, et al.

Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes

.

Cell Death Dis

.

2021

;

12

(

3

):

259

.

117.

Klein

C

,

Zwick

A

,

Kissel

S

, et al.

Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression

.

J Exp Med

.

2016

;

213

(

2

):

273

-

290

.

118.

Lin

TL

,

Wang

QH

,

Brown

P

, et al.

Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926

.

PLoS One

.

2010

;

5

(

12

):

e15262

.

119.

Yang

Y

,

Shi

J

,

Tolomelli

G

, et al.

RARα2 expression confers myeloma stem cell features

.

Blood

.

2013

;

122

(

8

):

1437

-

1447

.

120.

Bonnet

D

,

Dick

JE

.

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

.

Nat Med

.

1997

;

3

(

7

):

730

-

737

.

121.

Fukushima

N

,

Minami

Y

,

Kakiuchi

S

, et al.

Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells

.

Cancer Sci

.

2016

;

107

(

10

):

1422

-

1429

.

122.

Katagiri

S

,

Tauchi

T

,

Okabe

S

, et al.

Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia

.

Clin Cancer Res

.

2013

;

19

(

6

):

1422

-

1432

.

123.

Irvine

DA

,

Zhang

B

,

Kinstrie

R

, et al.

Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia

.

Sci Rep

.

2016

;

6

:

25476

.

124.

Farahani

M

,

Rubbi

C

,

Liu

L

,

Slupsky

JR

,

Kalakonda

N

.

CLL exosomes modulate the transcriptome and behaviour of recipient stromal cells and are selectively enriched in miR-202-3p

.

PLoS One

.

2015

;

10

(

10

):

e0141429

.

125.

Zhang

H

,

Chen

Z

,

Neelapu

SS

,

Romaguera

J

,

McCarty

N

.

Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment

.

Oncotarget

.

2016

;

7

(

12

):

14350

-

14365

.

126.

Alonso

S

,

Hernandez

D

,

Chang

YT

, et al.

Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance

.

J Clin Invest

.

2016

;

126

(

12

):

4460

-

4468

.

127.

Zhang

D

,

Huang

J

,

Wang

F

, et al.

BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions

.

Cell Death Dis

.

2021

;

12

(

5

):

495

.

128.

Manshouri

T

,

Veletic

I

,

Li

P

, et al.

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes

.

Cell Death Dis

.

2022

;

13

(

5

):

481

.

129.

Schneider

RK

,

Mullally

A

,

Dugourd

A

, et al.

Gli1⁺ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target

.

Cell Stem Cell

.

2017

;

20

(

6

):

785

-

800.e8

.

130.

Longhitano

L

,

Tibullo

D

,

Vicario

N

, et al.

IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis

.

Aging (Albany NY)

.

2021

;

13

(

23

):

25055

-

25071

.

131.

Bigelow

RL

,

Chari

NS

,

Unden

AB

, et al.

Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1

.

J Biol Chem

.

2004

;

279

(

2

):

1197

-

1205

.

132.

Regl

G

,

Kasper

M

,

Schnidar

H

, et al.

Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2

.

Cancer Res

.

2004

;

64

(

21

):

7724

-

7731

.

133.

Zhang

Q

,

Gong

W

,

Wu

H

, et al.

DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination

.

Carcinogenesis

.

2021

;

42

(

10

):

1223

-

1231

.

134.

Xie

Y

,

Liu

J

,

Jiang

H

, et al.

Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance Hedgehog signaling activity and drug resistance in multiple myeloma

.

Oncogene

.

2020

;

39

(

4

):

922

-

934

.

135.

Geng

Y

,

Liu

J

,

Xie

Y

, et al.

Trichostatin A promotes GLI1 degradation and P21 expression in multiple myeloma cells

.

Cancer Manag Res

.

2018

;

10

:

2905

-

2914

.

136.

Cai

K

,

Na

W

,

Guo

M

, et al.

Targeting the cross-talk between the Hedgehog and NF-κB signaling pathways in multiple myeloma

.

Leuk Lymphoma

.

2019

;

60

(

3

):

772

-

781

.

137.

Feng

L

,

Xu

X

,

Zhao

K

.

NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma

.

Leuk Res

.

2021

;

111

:

106708

.

138.

Xin

X

,

Ding

Y

,

Yang

Y

, et al.

Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic Hedgehog signaling

.

Blood Cancer J

.

2018

;

8

(

2

):

24

.

139.

Geng

L

,

Lu

K

,

Li

P

, et al.

GLI1 inhibitor GANT61 exhibits antitumor efficacy in T-cell lymphoma cells through down-regulation of p-STAT3 and SOCS3

.

Oncotarget

.

2017

;

8

(

30

):

48701

-

48710

.

140.

Fan

J

,

Zeng

X

,

Li

Y

, et al.

A novel therapeutic approach against B-cell non-Hodgkin's lymphoma through co-inhibition of Hedgehog signaling pathway and autophagy

.

Tumour Biol

.

2016

;

37

(

6

):

7305

-

7314

.

141.

Kern

D

,

Regl

G

,

Hofbauer

SW

, et al.

Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia

.

Oncogene

.

2015

;

34

(

42

):

5341

-

5351

.

142.

Desch

P

,

Asslaber

D

,

Kern

D

, et al.

Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells

.

Oncogene

.

2010

;

29

(

35

):

4885

-

4895

.

143.

Decker

S

,

Zirlik

K

,

Djebatchie

L

, et al.

Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL

.

Blood

.

2012

;

119

(

4

):

997

-

1007

.

144.

Hegde

GV

,

Peterson

KJ

,

Emanuel

K

, et al.

Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target

.

Mol Cancer Res

.

2008

;

6

(

12

):

1928

-

1936

.

145.

Qu

C

,

Liu

Y

,

Kunkalla

K

, et al.

Trimeric G protein-CARMA1 axis links smoothened, the Hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma

.

Blood

.

2013

;

121

(

23

):

4718

-

4728

.

146.

Agarwal

NK

,

Qu

C

,

Kunkalla

K

,

Liu

Y

,

Vega

F

.

Transcriptional regulation of serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1

.

J Biol Chem

.

2013

;

288

(

21

):

15390

-

15401

.

147.

Kunkalla

K

,

Liu

Y

,

Qu

C

, et al.

Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype

.

Ann Hematol

.

2013

;

92

(

6

):

777

-

787

.

148.

Ji

Z

,

Mei

FC

,

Johnson

BH

,

Thompson

EB

,

Cheng

X

.

Protein kinase A, not Epac, suppresses hedgehog activity and regulates glucocorticoid sensitivity in acute lymphoblastic leukemia cells

.

J Biol Chem

.

2007

;

282

(

52

):

37370

-

37377

.

149.

Bongiovanni

D

,

Tosello

V

,

Saccomani

V

, et al.

Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia

.

Oncogene

.

2020

;

39

(

42

):

6544

-

6555

.

150.

Li

X

,

Chen

F

,

Zhu

Q

, et al.

Gli-1/PI3K/AKT/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells

.

Oncotarget

.

2016

;

7

(

22

):

33004

-

33015

.

151.

Freisleben

F

,

Behrmann

L

,

Thaden

V

, et al.

Downregulation of GLI3 expression mediates chemotherapy resistance in acute myeloid leukemia

.

Int J Mol Sci

.

2020

;

21

(

14

):

5084

.

152.

Abd Elrhman

HE

,

Ebian

HF

.

Patched homolog 1 (PTCHI) gene mutations can predict the outcome of chronic myeloid leukemia patients?

.

Am J Blood Res

.

2019

;

9

(

2

):

15

-

24

.

153.

Abraham

A

,

Matsui

W

.

Hedgehog signaling in myeloid malignancies

.

Cancers

.

2021

;

13

(

19

):

4888

.

154.

Zhang

X

,

Liu

Y

,

Lu

L

, et al.

Oroxyloside A overcomes bone marrow microenvironment-mediated chronic myelogenous leukemia resistance to imatinib via suppressing Hedgehog pathway

.

Front Pharmacol

.

2017

;

8

:

526

.

155.

Zeng

X

,

Zhao

H

,

Li

Y

, et al.

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia

.

Autophagy

.

2015

;

11

(

2

):

355

-

372

.

156.

Zhou

H

,

Zhang

Z

,

Liu

C

, et al.

B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line

.

IUBMB Life

.

2012

;

64

(

11

):

889

-

900

.

157.

Shorstova

T

,

Foulkes

WD

,

Witcher

M

.

Achieving clinical success with BET inhibitors as anti-cancer agents

.

Br J Cancer

.

2021

;

124

(

9

):

1478

-

1490

.

158.

Axelson

M

,

Liu

K

,

Jiang

X

, et al.

U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma

.

Clin Cancer Res

.

2013

;

19

(

9

):

2289

-

2293

.

159.

Heuser

M

,

Smith

BD

,

Fiedler

W

, et al.

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

.

Ann Hematol

.

2021

;

100

(

5

):

1181

-

1194

.

160.

Lin

S

,

Shaik

N

,

Chan

G

,

Cortes

JE

,

Ruiz-Garcia

A

.

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure

.

Cancer Chemother Pharmacol

.

2020

;

86

(

4

):

451

-

459

.

161.

Cortes

JE

,

Heidel

FH

,

Fiedler

W

, et al.

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

.

J Hematol Oncol

.

2020

;

13

(

1

):

92

.

162.

Cortes

JE

,

Heidel

FH

,

Hellmann

A

, et al.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

.

Leukemia

.

2019

;

33

(

2

):

379

-

389

.

163.

Cortes

JE

,

Douglas Smith

B

,

Wang

ES

, et al.

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results

.

Am J Hematol

.

2018

;

93

(

11

):

1301

-

1310

.

164.

Savona

MR

,

Pollyea

DA

,

Stock

W

, et al.

Phase Ib study of glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS

.

Clin Cancer Res

.

2018

;

24

(

10

):

2294

-

2303

.

165.

Shah

NP

,

Cortes

JE

,

Martinelli

G

, et al.

Dasatinib plus Smoothened (SMO) inhibitor BMS-833923 in chronic myeloid leukemia (CML) with resistance or suboptimal response to a prior tyrosine kinase inhibitor (TKI): phase I study CA180323

.

Blood

.

2014

;

124

(

21

):

4539

.

166.

Gupta

V

,

Harrison

CN

,

Hasselbalch

H

, et al.

Phase 1b/2 study of the efficacy and safety of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis

.

Blood

.

2015

;

126

(

23

):

825

.

167.

Couban

S

,

Benevolo

G

,

Donnellan

W

, et al.

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

.

J Hematol Oncol

.

2018

;

11

(

1

):

122

.

168.

Buadi

FK

,

Lacy

MQ

,

Dispenzieri

A

, et al.

Phase 2 trial of LDE225 and lenalidomide maintenance post autologous stem cell transplant for multiple myeloma

.

Blood

.

2019

;

134

(

suppl 1

):

1905

.

169.

Assouline

S

,

Gasiorek

J

,

Bergeron

J

, et al.

Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine

.

Haematol

.

2023

.

170.

Cortes

JE

,

Dombret

H

,

Merchant

A

, et al.

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 phase III trials

.

Future Oncol

.

2019

;

15

(

31

):

3531

-

3545

.

171.

Jaramillo

S

,

Krisam

J

,

Le Cornet

L

, et al.

Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML

.

Trials

.

2021

;

22

(

1

):

765

.

172.

Short

NJ

,

Borthakur

G

,

Pemmaraju

N

, et al.

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

.

Leuk Lymphoma

.

2022

;

63

(

9

):

2161

-

2170

.

173.

Bhatt

VR

,

Wichman

C

,

Al-Kadhimi

ZS

, et al.

Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia

.

J Geriatr Oncol

.

2022

;

13

(

6

):

871

-

874

.

174.

Fostvedt

LK

,

Shaik

N

,

Martinelli

G

,

Wagner

AJ

,

Ruiz-Garcia

A

.

Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer

.

Expert Rev Clin Pharmacol

.

2021

;

14

(

7

):

927

-

935

.

175.

Martinelli

G

,

Oehler

VG

,

Papayannidis

C

, et al.

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study

.

Lancet Haematol

.

2015

;

2

(

8

):

e339

-

346

.

176.

Minami

Y

,

Minami

H

,

Miyamoto

T

, et al.

Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies

.

Cancer Sci

.

2017

;

108

(

8

):

1628

-

1633

.

177.

Sekeres

MA

,

Schuster

M

,

Joris

M

, et al.

A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes

.

Ann Hematol

.

2022

;

101

(

8

):

1689

-

1701

.

178.

Kent

A

,

Vasu

S

,

Schatz

D

, et al.

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse

.

Blood Adv

.

2020

;

4

(

13

):

3102

-

3108

.

179.

Gerds

AT

,

Tauchi

T

,

Ritchie

EK

, et al.

Phase I/II trial of glasdegib in patients with primary or secondary myelofibrosis

.

J Clin Oncol

.

2017

;

35

(

15 suppl

):

7061

.

180.

Sasaki

K

,

Gotlib

JR

,

Mesa

RA

, et al.

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

.

Leuk Lymphoma

.

2015

;

56

(

7

):

2092

-

2097

.

181.

Tibes

R

,

Kosiorek

HE

,

Dueck

A

, et al.

Phase I/IB study of azacitidine and Hedgehog pathway inhibition with sonidegib (LDE225) in myeloid malignancies

.

Blood

.

2017

;

130

(

suppl 1

):

2629

.

182.

Tibes

R

,

Kosiorek

HE

,

Dueck

AC

, et al.

Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms

.

Cancer

.

2023

;

129

(

15

):

2321

-

2330

.

183.

Bixby

D

,

Noppeney

R

,

Lin

TL

, et al.

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

.

Br J Haematol

.

2019

;

185

(

3

):

595

-

598

.

184.

Houot

R

,

Soussain

C

,

Tilly

H

, et al.

Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA

.

Ann Oncol

.

2016

;

27

(

7

):

1349

-

1350

.